Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.62 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.61 |
| ▸ | P2RY10 | O00398 | 11/20 | 0.60 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.60 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31374407 | 1.00 | DGKA (0.62) | DGKANOD1P2RY10GPR34GPR174 | |
| SCHEMBL8578438 | 0.91 | NOD1 (0.69) | DGKANOD1P2RY10GPR34GPR174 | |
| SCHEMBL8768982 | 0.90 | NOD1 (0.64) | DGKANOD1P2RY10GPR34GPR174 | |
| SCHEMBL8768987 | 0.90 | NOD1 (0.64) | DGKANOD1P2RY10GPR34GPR174 | |
| SCHEMBL17537068 | 0.87 | NOD1 (0.64) | DGKANOD1P2RY10GPR34 | |
| SCHEMBL9005485 | 0.87 | NOD1 (0.64) | DGKANOD1P2RY10GPR34 | |
| SCHEMBL17537075 | 0.87 | NOD1 (0.64) | DGKANOD1P2RY10GPR34 | |
| SCHEMBL17010720 | 0.87 | NOD1 (0.64) | DGKANOD1P2RY10GPR34 | |
| SCHEMBL15260354 | 0.87 | NOD1 (0.64) | DGKANOD1P2RY10GPR34 | |
| SCHEMBL7351258 | 0.87 | NOD1 (0.64) | DGKANOD1P2RY10GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130316957-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV (US) | 2013-11-28 | — | — | US | disclosed |
| US-8546524-B2 | Smoothened polypeptides and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120282196-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2012-11-08 | — | — | US | disclosed |
| US-8198402-B2 | Smoothened polypeptides and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-06-12 | — | — | US | disclosed |
| EP-2431388-A1 | Smoothened polypeptides and methods of use | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20100093625-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICE (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2078036-A2 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008070357-A9 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | US GOV HEALTH & HUMAN SERV (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008070357-A2 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093625-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | SMO, SHH, GLI1 | DGKA 195/4885NOD1 4225/4885P2RY10 4413/4885 |
| US-20130316957-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | SMO, SHH, GLI1 | DGKA 195/4885NOD1 4225/4885P2RY10 4413/4885 |
| US-20120282196-A1 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | SMO, SHH, GLI1 | DGKA 195/4885NOD1 4225/4885P2RY10 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.